Compare Stocks

→ How to camouflage a factory of 53,000 workers (From Stansberry Research) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KHTRF Knight Therapeutics	$4.19	$4.03	$3.20 ▼ $4.29	N/A	N/A	7,205 shs	2,200 shs
THCX AXS Cannabis ETF	$16.60	$16.61	$14.90 ▼ $25.40	$141.07M	1.71	15,071 shs	N/A

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KHTRF Knight Therapeutics	0.00%	0.00%	+7.71%	+3.97%	+17.56%
THCX AXS Cannabis ETF	0.00%	0.00%	0.00%	-2.32%	-17.84%

This Apple-like Innovator is Revolutionizing Healthcare (Ad)

AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.

Click here to learn more about the booming eHealth industry

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
KHTRF Knight Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
THCX AXS Cannabis ETF	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KHTRF Knight Therapeutics	3.00	Buy	$7.50	79.00% Upside
THCX AXS Cannabis ETF	0.00	N/A	$21.88	31.84% Upside

Current Analyst Ratings

Latest KHTRF and THCX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
3/6/2024	KHTRF Knight Therapeutics	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$7.00 ➝ $7.50

(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KHTRF Knight Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
THCX AXS Cannabis ETF	N/A	N/A	N/A	N/A	N/A	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KHTRF Knight Therapeutics	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	5/9/2024 (Estimated)
THCX AXS Cannabis ETF	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
KHTRF Knight Therapeutics	N/A	N/A	N/A	N/A	N/A
THCX AXS Cannabis ETF	$0.03	0.18%	N/A	N/A	N/A

Ownership

Institutional Ownership

Company	Institutional Ownership
KHTRF Knight Therapeutics	24.85%
THCX AXS Cannabis ETF	N/A

Insider Ownership

Company	Insider Ownership
KHTRF Knight Therapeutics	N/A
THCX AXS Cannabis ETF	N/A

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
KHTRF Knight Therapeutics	725	N/A	N/A	Not Optionable
THCX AXS Cannabis ETF	N/A	8.50 million	N/A	Not Optionable

KHTRF and THCX Headlines

Source	Headline
	AdvisorShares Pure Cannabis ETF declares quarterly distribution of $0.0281 msn.com - March 22 at 3:35 PM
	This Week in ETFs: 7 New ETFs Dwarfed by 11 Closures etftrends.com - February 23 at 8:37 PM
	This Week in ETFs: Just 5 New Funds in Quiet Week etftrends.com - February 9 at 1:46 PM
	THCX: Another Cannabis ETF Closes Down thedeepdive.ca - February 8 at 2:13 PM
	Craig-Hallum Upgrades Village Farms International (VFF) msn.com - November 9 at 8:30 PM
	THCX ETF Stock Price History investing.com - October 29 at 8:29 AM
	Cannabis company Trulieve weighing options after ex-CFO allegedly charged company up to $400,000 for ‘personal expenses’ msn.com - August 10 at 11:37 AM
	UK's Medical Cannabis Trial, Training Farmers And Medical Professionals In Morocco & More Global Updates benzinga.com - August 3 at 12:58 AM
	Benchmark Initiates Coverage of Greenlane Holdings Inc - (GNLN) with Speculative Hold Recommendation msn.com - June 10 at 2:26 AM
	High Tide (TSX:HITI) Price Target Increased by 17.82% to 6.97 msn.com - May 11 at 9:05 PM
	Best Cannabis ETFs Right Now benzinga.com - March 3 at 11:26 PM
	California’s Marijuana Paradise Lost wsj.com - February 7 at 7:52 PM
	What Cannabis Stocks Should Be In Your Portfolio? seekingalpha.com - February 2 at 11:47 PM
	420 with CNW — Why Cannabis Firms Should Look Elsewhere for Financing markets.buffalonews.com - February 1 at 5:00 PM
	American and Canadian Cannabis Advertising Regulations Show Lack of Consistency in the US labroots.com - February 1 at 12:00 PM
	Green Check Verified Launches Marketplace to Provide Cannabis Industry Access to Network of Reputable Financial and Business Services Providers markets.buffalonews.com - January 31 at 9:27 AM
	Why Google, Netflix, and cannabis dispensaries are using this century-old sign technology fastcompany.com - January 28 at 5:35 AM
	420 with CNW — Texas Authorities Start Process to Issue Additional Medical Marijuana Dispensary Licenses markets.buffalonews.com - January 27 at 5:36 PM
	Publicly traded cannabis fintech POSaBIT acquires three compliance software firms msn.com - January 27 at 7:35 AM
	How a St. Louis entrepreneur is making cannabis shopping easier bizjournals.com - January 26 at 4:32 PM
	Sundial Growers (SNDL) Stock Fell To 13 Cents During COVID Pandemic — How Much Is A $1,000 Investment At The Low Worth Now? msn.com - January 26 at 11:32 AM
	420 with CNW — Las Vegas Prepares to Launch First Marijuana Hotel in April markets.buffalonews.com - January 25 at 5:20 PM
	Aurora Cannabis Inc. Common Shares (ACB) nasdaq.com - January 21 at 7:50 AM
	Cannabis Is A Commodity seekingalpha.com - January 18 at 11:46 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Knight Therapeutics

OTCMKTS:KHTRF

Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company provides Ladecvina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.

AXS Cannabis ETF

NYSEARCA:THCX

The Cannabis ETF (THCX) is an exchange-traded fund that is based on the AXS Cannabis index. The fund tracks an index of legal cannabis companies selected and weighted by market capitalization. The fund primarily holds North American companies but may also invest in other countries. THCX was launched on Jul 9, 2019 and is managed by AXS Investments.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial